ATRA+ATO+蒽环类三联疗法治疗非高危成人APL疗效评估  

Therapeutic effect analysis of ATRA+ATO+anthracycline triple combination therapy in the treatment of non-high-risk adult acute promyelocytic leukemia

作　　者：张楠楠 刘晶晶 曾先 Zhang Nannan;Liu Jingjing;Zeng Xian(Department of Hematology,The First Affiliated Hospital of Henan University of Science and Technology,Luoyang 471000,China)

机构地区：[1]河南科技大学第一附属医院血液内科,河南洛阳471000

出　　处：《华北理工大学学报（医学版）》2024年第4期301-305,共5页Journal of North China University of Science and Technology：Health Sciences Edition

摘　　要：目的探讨全反式维甲酸(ATRA)+亚砷酸(ATO)+蒽环类三联方案对成人非高危急性早幼粒细胞白血病(APL)的治疗效果。方法选取2018年1月~2022年1月在河南科技大学第一附属医院治疗的成人非高危APL患者88例,采用信封法分为观察组和对照组各44例,观察组给予ATRA+ATO+蒽环类三联方案,对照组给予ATRA+ATO,观察两组治疗效果、凝血功能及生活质量改善情况。结果观察组达到完全缓解(CR)时间快于对照组,凝血反应时间(R)、血凝块形成时间(K)和凝血酶原时间(PT)低于对照组,Angle角(Angle)、最大振幅(MA)和纤维蛋白原(Fib)高于对照组(P<0.05)。观察组治疗后生活质量核心量表(EORTC QLQ-C30)疲劳得分低于对照组,而总体健康状况得分高于对照组(P<0.05)。结论ATRA+ATO+蒽环类三联方案治疗成人非高危APL效果好,可改善凝血功能、提高生活质量。Objective To investigate the therapeutic effect of all-trans retinoic acid(ATRA)+arsenic trioxide(ATO)+anthracycline triple combination therapy on adult non-high-risk acute promyelocytic leukemia(APL).Methods A total of 88 adult non-high-risk APL patients treated in the First Affiliated Hospital of Henan University of Science and Technology from January 2018 to January 2022 were selected and divided into an observation group and a control group using the envelope method,with 44 patients in each group.The observation group was given ATRA+ATO+anthracycline triple combination therapy,while the control group was given ATRA+ATO.The therapeutic effect,coagulation function,and improvement in quality of life were observed in both groups.Results The time to achieve complete remission(CR)in the observation group was faster than that in the control group.The coagulation reaction time(R),clot formation time(K),and prothrombin time(PT)were lower in the observation group than in the control group,while the Angle,maximum amplitude(MA),and fibrinogen(FIB)were higher(P<0.05).After treatment,the fatigue score on the EORTC QLQ-C30 scale was lower in the observation group than in the control group,while the overall health status score was higher(P<0.05).Conclusion ATRA+ATO+anthracycline triple combination therapy has good therapeutic effects in the treatment of adult non-high-risk acute promyelocytic leukemia,and can improve coagulation function and quality of life.

关 键 词：全反式维甲酸 亚砷酸 蒽环类 成人 非高危 急性早幼粒细胞白细胞 

分 类 号：R733[医药卫生—肿瘤]